{"Clinical Trial ID": "NCT00072293", "Intervention": ["INTERVENTION 1:", "Axillary dissection", "Patients undergo a surgical resection of the primary tumour with dissection of the axillary lymph nodes after evaluation of sentinel lymph nodes.", "Dissection of axillary lymph nodes: Dissection of axillary lymph nodes", "INTERVENTION 2:", "No axillary dissection", "Patients undergo a surgical resection of the primary tumour without dissection of the axillary lymph nodes after evaluation of sentinel lymph nodes.", "No dissection of axillary lymph nodes: conventional therapeutic surgery"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "- Clinical, mammographic, ultrasonic or pathological diagnosis of unicentric and unifocal breast carcinoma", "The biggest tumour lesion 5 cm", "\u2022 Palpable or non-palpable breast injury", "Location of preoperative occult lesions, hook wire or other method of location required for non-palpable lesions", "\u2022 Previous (preoperative) or planned (intraoperative) sentinel nodes biopsy is required", "At least 1 micrometastatic (i.e. not more than 2 mm) sentinel lymph node without extracapsular extension", "No clinical evidence of distant metastases", "No suspicious manifestations of metastases that cannot be excluded by X-ray, MRI or scanner, including:", "Skeletal pain of unknown cause", "High alkaline phosphatase", "\u2022 Bone scan showing hot spots", "No palpable axillary lymph nodes", "No Paget disease without invasive cancer", "- Hormonal receptor status:", "Estrogen receptor and known progesterone receptor", "CHARACTERISTICS OF PATIENTS:", "Age", "Whatever the age", "Gender", "Women", "Status of menopause", "Any status", "State of play", "Unspecified", "Life expectancy", "Unspecified", "Haematopoietic", "Unspecified", "Hepatic", "See Disease Characteristics", "Renal", "Unspecified", "Other", "No pregnancy or breast-feeding", "No other prior or concomitant malignancy except:", "Skin cancer of basal or squamous cells", "\u2022 Properly treated in situ carcinoma of the cervix", "A properly treated melanoma in situ", "A contralateral or in situ ipsilateral carcinoma of the breast", "No psychiatric, addictive or other disorders that could compromise the ability to give informed consent", "Geographically accessible for monitoring", "THERAPE PRIOR CONCURENT:", "Biological therapy", "Unspecified", "- Chemotherapy", "Unspecified", "Endocrinotherapy", "Unspecified", "Radiotherapy", "Unspecified", "Surgery", "See Disease Characteristics", "Other", "No previous systemic treatment for breast cancer", "More than a year since previous chemopreventive agent"], "Results": ["Performance measures:", "5 years of disease-free survival", "\u25cf Estimated percentage of live and disease-free patients at 5 years of randomization, where disease-free survival is defined as the time of randomization at the first evidence of invasive relapse at any site, second primary tumour (contralateral or non-brassial) or death.", "Time frame: estimate of 5 years after median follow-up of 60 months", "Results 1:", "Title of arm/group: Axillary dissection", "Description of the arm/group: Patients undergo a surgical resection of the primary tumour with dissection of the axillary lymph nodes after evaluation of sentinel lymph nodes.", "Dissection of axillary lymph nodes: Dissection of axillary lymph nodes", "Total number of participants analysed: 464", "Type of measurement: Number", "Unit of measure: percentage of participants 84.4", "Results 2:", "Title of arm/group: No axillary dissection", "Description of the arm/group: Patients undergo a surgical resection of the primary tumour without axillary dissection of the lymph nodes after sentinel evaluation of the lymph nodes.", "No dissection of axillary lymph nodes: conventional therapeutic surgery", "Total number of participants analysed: 467", "Type of measurement: Number", "Unit of measure: percentage of participants 87.8"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/447 (0.22%)", "1/447 (0.22%)", "Adverse Events 2:", "Total: 0/453 (0.00 per cent)", "- Postoperative infection (L.axilla) 0/453 (0.00 %)"]}